Loading
If this is the first time anyone has visited this substance, we may be fetching live data from TGA Product Information, PBS, and state framework sources — that can take up to a minute. Cached substances load in a second or two.
Curated subset. The full adverse-effect list is in the TGA Product Information; click any citation above to open it.
“Teprotumumab is a monoclonal antibody (IgG1) that binds to the insulin-like growth factor-1 receptor (IGF-1R) and blocks its activation and signalling.”
“Following the recommended teprotumumab dosing regimen, the population PK estimated mean (± standard deviation) for the clearance of teprotumumab was 0.27 (± 0.07) L/day and for the elimination half-life was 22 (± 4) days.”
Working under the parallel aged-care framework? Aged-care equivalent →